These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33966663)

  • 21. Battle lines shift in stem-cell funding fight...as non-profit companies enter the fray.
    Smaglik P
    Nature; 2000 May; 405(6782):6. PubMed ID: 10811186
    [No Abstract]   [Full Text] [Related]  

  • 22. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Australia's 'free-ride' in pharmaceuticals: can it last?
    Kemp R
    Aust Health Rev; 1996; 19(1):81-94. PubMed ID: 10157539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):627-36. PubMed ID: 24953125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceutical drug development: high drug prices and the hidden role of public funding.
    Annett S
    Biol Futur; 2021 Jun; 72(2):129-138. PubMed ID: 34554467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Non-Profit Approach to Address Foreign Dependence of Generic Drugs.
    Liljenquist D; Bai G; Sarpatwari A; Anderson GF
    J Law Med Ethics; 2021; 49(1):30-33. PubMed ID: 33966649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Public-sector Contributions to Novel Biologic Drugs.
    Nayak RK; Lee CC; Avorn J; Kesselheim AS
    JAMA Intern Med; 2021 Nov; 181(11):1522-1525. PubMed ID: 34279545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 30. Discriminatory pricing lawsuits could change future of community pharmacy.
    Flanagan ME
    Am Pharm; 1994 Oct; NS34(10):20-3. PubMed ID: 7992787
    [No Abstract]   [Full Text] [Related]  

  • 31. Doing "good" vs. doing "well": the role of nonprofits in society.
    Berman HJ
    Inquiry; 2002; 39(1):5-11. PubMed ID: 12067075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drugs firms inflate research costs, watchdog says.
    Knight J
    Nature; 2001 Aug; 412(6847):571. PubMed ID: 11493879
    [No Abstract]   [Full Text] [Related]  

  • 33. Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
    Sarpatwari A; Avorn J; Kesselheim AS
    BMJ; 2020 Oct; 371():m3841. PubMed ID: 33032982
    [No Abstract]   [Full Text] [Related]  

  • 34. Eurofile. Private-public drive to cut delays in drug development.
    Mundell I
    Eur J Cancer; 2008 Jan; 44(2):169. PubMed ID: 18335586
    [No Abstract]   [Full Text] [Related]  

  • 35. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 36. Public/private-sector collaboration in contraceptive research and development: summary and historical perspective.
    Spieler J
    Int J Gynaecol Obstet; 1999 Dec; 67 Suppl 2():S13-22. PubMed ID: 10661737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The quasi-market for adult residential care in the UK: Do for-profit, not-for-profit or public sector residential care and nursing homes provide better quality care?
    Barron DN; West E
    Soc Sci Med; 2017 Apr; 179():137-146. PubMed ID: 28273611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health.
    Gagnon MA
    J Law Med Ethics; 2013; 41(3):571-80. PubMed ID: 24088147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.
    Matter A; Keller TH
    Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public-private health partnerships: a strategy for WHO.
    Buse K; Waxman A
    Bull World Health Organ; 2001; 79(8):748-54. PubMed ID: 11545332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.